Q1 2024 Vimian Group AB Earnings Call Transcript
I'd like to start our call by going through a couple of highlights. First of all, we operate in a solid market and the growth continues to be robust, and we have made a decision to reduce our AOP program this year, which is in our MedTech business where we are normalizing and facing our revenues throughout the year. This is to match the customers' consumption with their deliveries and to streamline our supply chain and to be able to operate our business with lower working capital, both in inventory and accounts receivable. And this change of this offer to our customers to move from annualized order programs where they would buy a full year consumption at the beginning of the year to switch over to a quarterly or a monthly order pattern has impacted our first quarter growth.
And in our MedTech segment, this has no impact on our full year revenue and the gap that was created in Q1 will be fully recovered throughout the remaining and quarters of the year. We have strong momentum in our both in our vet services business and in our specialty pharma business. Both
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
